Cargando…

Antibody Generation and Immunogenicity Analysis of EBV gp42 N-Terminal Region

Epstein–Barr virus (EBV) is the first reported oncogenic virus and infects more than 90% of adults worldwide. EBV can establish a latent infection in B lymphocytes which is essential for persistence and transmission. Glycoprotein gp42 is an indispensable member of the triggering complex for EBV entr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Junping, Wei, Dongmei, Wu, Qian, Zhong, Ling, Chen, Kaiyun, Huang, Yang, Zhang, Wanlin, Chen, Junyu, Xia, Ningshao, Zhang, Xiao, Chen, Yixin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707153/ https://www.ncbi.nlm.nih.gov/pubmed/34960650 http://dx.doi.org/10.3390/v13122380

Ejemplares similares

Neutralizing antibodies against EBV gp42 show potent in vivo protection and define novel epitopes
por: Wu, Qian, et al.
Publicado: (2023)

Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells
por: Hong, Junping, et al.
Publicado: (2022)

Non-overlapping epitopes on the gHgL-gp42 complex for the rational design of a triple-antibody cocktail against EBV infection
por: Hong, Junping, et al.
Publicado: (2023)

Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion
por: Zhang, Xiao, et al.
Publicado: (2022)

Dose-Dependent Outcome of EBV Infection of Humanized Mice Based on Green Raji Unit (GRU) Doses
por: Chen, Haiwen, et al.
Publicado: (2021)

Rabbit Monoclonal Antibody Specifically Recognizing a Linear Epitope in the RBD of SARS-CoV-2 Spike Protein
por: Hong, Junping, et al.
Publicado: (2021)

Generation of novel affibody molecules targeting the EBV LMP2A N-terminal domain with inhibiting effects on the proliferation of nasopharyngeal carcinoma cells
por: Zhu, Jinshun, et al.
Publicado: (2020)

Correction: Generation of novel affibody molecules targeting the EBV LMP2A N-terminal domain with inhibiting effects on the proliferation of nasopharyngeal carcinoma cells
por: Zhu, Jinshun, et al.
Publicado: (2020)

Development of an Improved Epstein-Barr Virus (EBV) Neutralizing Antibody Assay to Facilitate Development of a Prophylactic gp350-Subunit EBV Vaccine
por: Liu, Hui, et al.
Publicado: (2020)

Clinical analysis of 42 cases of EBV-positive mature T/NK-cell neoplasms
por: Yang, Haiyan, et al.
Publicado: (2017)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
por: Mata-Fink, J, et al.
Publicado: (2012)

A high-throughput neutralizing assay for antibodies and sera evaluation against Epstein-Barr virus
por: Zhong, Ling, et al.
Publicado: (2022)

The diagnostic value of EBV-DNA and EBV-related antibodies detection for nasopharyngeal carcinoma: a meta-analysis
por: Liu, Weixing, et al.
Publicado: (2021)

P19-42. Engineering, expression and antigenic and immunogenic characterization of novel soluble clade A/B heterotrimeric gp140-envelope glycoproteins
por: Sellhon, G, et al.
Publicado: (2009)

Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA
por: Zhang, Aixia, et al.
Publicado: (2012)

Immunogenicity of the outer domain of a HIV-1 clade C gp120
por: Chen, Hongying, et al.
Publicado: (2007)

Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation
por: Deng, Tingting, et al.
Publicado: (2022)

Development of functional antibodies against influenza B virus by activation-induced cytidine deaminase in hybridoma cells
por: Chen, Yuanzhi, et al.
Publicado: (2022)

Increased frequency of T cells specific for EBV gp110 in the synovial fluid of patients with rheumatoid arthritis
por: Toussirot, E, et al.
Publicado: (2003)

Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma
por: Zhu, Shanli, et al.
Publicado: (2020)

Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines
por: Wang, Shixia, et al.
Publicado: (2017)

Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2013)

The immunogenicity and protective immunity of multi-epitopes DNA prime-protein boost vaccines encoding Amastin-Kmp-11, Kmp11-Gp63 and Amastin-Gp63 against visceral leishmaniasis
por: Zhang, Jianhui, et al.
Publicado: (2020)

Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein
por: Vassell, Russell, et al.
Publicado: (2015)

Performance of Plasma HSP90α, Serum EBV VCA IgA Antibody and Plasma EBV DNA for the Diagnosis and Prognosis Prediction of Nasopharyngeal Carcinoma
por: Ye, Qian, et al.
Publicado: (2021)

Hyperglycosylated resurfaced stabilized GP120 core as an immunogen elicits antibodies targeted at the CD4-binding site
por: Dai, K, et al.
Publicado: (2012)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2014)

Retraction: Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector
Publicado: (2020)

HKDC1 C-terminal based peptides inhibit extranodal natural killer/T-cell lymphoma by modulation of mitochondrial function and EBV suppression
por: Chen, Qi, et al.
Publicado: (2020)

Generating CTLs against the subdominant EBV LMP antigens by transit expression of an A20 inhibitor with EBV LMP proteins in human DCs
por: Hong, Bangxing, et al.
Publicado: (2011)

Construction and immunogenicity of a DNA vaccine coexpressing GP3 and GP5 of genotype-I porcine reproductive and respiratory syndrome virus
por: Ren, Jing-Qiang, et al.
Publicado: (2014)

A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice
por: Ogembo, Javier Gordon, et al.
Publicado: (2015)

Production and Immunogenicity of Soluble Plant-Produced HIV-1 Subtype C Envelope gp140 Immunogens
por: Margolin, Emmanuel, et al.
Publicado: (2019)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

Designing and overproducing a tandem epitope of gp350/220 that shows a potential to become an EBV vaccine
por: Widodo, et al.
Publicado: (2018)

Vaccination with Deglycosylated Modified Hemagglutinin Broadly Protects against Influenza Virus Infection in Mice and Ferrets
por: Zhang, Limin, et al.
Publicado: (2022)

P19-06. The first hypervariable loop and HIV-1 neutralizing antibodies elicited by gp140 env immunogens
por: Ching, LK, et al.
Publicado: (2009)

Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies
por: Doran, Rachel C., et al.
Publicado: (2018)

EBV-induced T-cell responses in EBV-specific and nonspecific cancers
por: Zhang, Qiuting, et al.
Publicado: (2023)

Characterization and Immunogenicity of HIV Envelope gp140 Zera(®) Tagged Antigens
por: Ximba, Phindile, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hqkdgm637gau3h4c11og7qll5r